Brief: Takeda's ENTYVIO Shows Promise For Treating Ulcerative Colitis In Children
19/02/2026 17:40
Feb 19 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: POSITIVE PHASE 3 DATA DEMONSTRATE POTENTIAL FOR ENTYVIO® (VEDOLIZUMAB) TO ADDRESS TREATMENT GAP FOR CHILDREN AND ADOLESCENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS TAKEDA PHARMACEUTICAL CO LTD: VEDOLIZUMAB'S SAFETY PROFILE WAS GENERALLY CONSISTENT WITH ITS KNOWN SAFETY PROFILE IN ADULTS Source text: ID:nBw5ssxjSa Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)